Bolt Biotherapeutics (NASDAQ:BOLT) COO Sells $22,194.00 in Stock

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) COO Grant Yonehiro sold 6,850 shares of the business’s stock in a transaction on Friday, September 18th. The shares were sold at an average price of $3.24, for a total transaction of $22,194.00. Following the completion of the sale, the chief operating officer directly owned 17,269 shares in the company, valued at $55,951.56. This represents a 28.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Grant Yonehiro also recently made the following trade(s):

• On Thursday, September 17th, Grant Yonehiro sold 4,909 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.32, for a total transaction of $16,297.88.
• On Wednesday, September 16th, Grant Yonehiro sold 1,417 shares of Bolt Biotherapeutics stock. The stock was sold at an average price of $3.77, for a total value of $5,342.09.

Bolt Biotherapeutics Stock Up 0.8%

BOLT stock traded up $0.03 during trading hours on Monday, reaching $3.59. 22,454 shares of the stock were exchanged, compared to its average volume of 27,365. The firm’s 50-day moving average is $3.84 and its 200-day moving average is $4.29. Bolt Biotherapeutics, Inc. has a 12 month low of $3.10 and a 12 month high of $7.20. The company has a market cap of $6.93 million, a price-to-earnings ratio of -0.22 and a beta of 1.09. The company has a debt-to-equity ratio of 1.47, a current ratio of 2.61 and a quick ratio of 2.61.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($4.57) EPS for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The firm had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. On average, equities research analysts expect that Bolt Biotherapeutics, Inc. will post -11.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price target on shares of Bolt Biotherapeutics in a research report on Thursday, May 28th. Rodman & Renshaw initiated coverage on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. They issued a “buy” rating and a $22.00 price objective on the stock. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Friday, July 17th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.50.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its holdings in shares of Bolt Biotherapeutics by 40.3% during the first quarter. Renaissance Technologies LLC now owns 77,225 shares of the company’s stock worth $312,000 after buying an additional 22,200 shares in the last quarter. T3 Companies LLC bought a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $208,000. Finally, Nan Fung Group Holdings Ltd acquired a new stake in shares of Bolt Biotherapeutics in the 2nd quarter valued at $19,250. 86.70% of the stock is currently owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s platform is designed to stimulate the body’s innate and adaptive immune systems to recognize and attack tumor cells.

Bolt’s technology includes Boltbody™ immune-stimulating antibody conjugates, or ISACs. These therapies are intended to combine the targeting capabilities of antibodies with immune-activating components that can recruit and enhance the activity of immune cells within the tumor microenvironment.

The company’s development programs have included BDC-1001, an investigational HER2-targeted ISAC for the treatment of HER2-expressing solid tumors, and BDC-3042, an investigational antibody intended to activate macrophages through the Dectin-2 pathway.